2024年环境、社会及管治报告

AscentagePharmaGroupInternational (IncorporatedintheCaymanIslandswithlimitedliability)StockCode:HKEX:6855NASDAQ:AAPG APG-2449 Olverembatinib (HQP1351) APG-5918 Pelcitoclax (APG-1252) Alrizomadlin (APG-115) 2024 Lisaftoclax (APG-2575) Environmental,SocialandGovernanceReport Contents Page 1 AboutthisReport2 HighlightsandPerformance3 MessagefromManagement4 AboutAscentagePharma6 1CorporateGovernanceandSolidFoundations7 1.1CorporateGovernance7 1.2BusinessEthics13 2GlobalPresence&R&DandInnovation15 2.1R&DandInnovation15 2.2IntellectualPropertyRights25 2.3R&DEthicsandMorals26 3StrictQualityControlandSustainableSupply28 3.1QualityandSafety28 3.2ServiceExcellence39 3.3SupplyChainManagement41 4GreenProduction,SafetyAssurance49 4.1EnvironmentalManagement49 4.2TacklingClimateChange54 4.3EmissionManagement64 4.4OccupationalHealthandSafety67 5EmpoweringTalentstoCreateWarmthTogether73 5.1Employment73 5.2TalentDevelopment76 5.3CareandWelfare83 5.4WelcomingCommunity88 AppendixI–ESGKeyPerformanceIndicators(KPIs)90 AppendixII–HongKongStockExchangeEnvironmental, SocialandGovernanceReportingCodeContentIndex95 Environmental,SocialandGovernanceReport2024AscentagePharmaGroupInternational 2 Environmental,SocialandGovernanceReport2024 AboutthisReport ReportReview ThisReportisthesixthEnvironmental,SocialandGovernance(hereinafter“ESG”)ReportpublishedbyAscentagePharmaGroupInternational(hereinafterthe“Company”orthe“Group”)anditssubsidiaries(hereinafter“AscentagePharma”or“Ascentage”or“we”or“us”). ReportingGuidelines TheReporthasbeenpreparedinaccordancewiththeEnvironmental,SocialandGovernanceReportingCode(hereinafterthe“ESGReportingCode”)underAppendixC2totheRulesGoverningtheListingofSecuritiesissuedbyTheStockExchangeofHongKongLimited(hereinafterthe“HongKongStockExchange”)effectivefromDecember2023onwards. ScopeofReport Timeframe:TheReportcoverstheperiodbetweenJanuary1,2024andDecember31,2024(hereinafterthe“ReportingPeriod”orthe“Year”or“2024”),whereascertaincontentwouldbeinaretrospectiveorprospectivebasis(asappropriate)toenhancecompletenessoftheReport. Scopeofreport:ThecontentoftheReportcoversAscentagePharmaGroupInternationalanditssubsidiaries,includingAscentagePharma(HK),AscentageJiangsu,AscentageSuzhou,AscentageShanghai,HealthquestPharma,AscentageUS,AscentageAustralia,AscentageInternationalandAscentageInvestment. DataSourceandDescription TheinformationanddatausedinthisReportarecollectedfromtheofficialdocumentsandstatisticalreportsoftheGroup,whichhavebeenreviewedbyrelevantdepartments.Unlessotherwisespecified,thecurrencyinthisReportisRenminbi(RMB). ReliabilityAssuranceandApproval TheGrouphasnotfoundanyfalserecord,misleadingstatementormaterialomissioninthisReport.ThisReportcomplieswithallthe“complyorexplain”provisionsintheESGReportingCodeandpreparedaccordingtothereportingprinciplesofmateriality,quantitativeandbalanceintheESGReportingCode.ThisReportwasapprovedbytheBoardofDirectorsonApril15,2025. AccessandResponsetotheReport ThisReportisavailableinTraditionalChineseandEnglishforreaders’reference.ThisReportcanbefoundwithinthecategoryofFinancialStatements/ESGInformation,ontheHKEXnewswebsiteortheofficialwebsiteofAscentagePharma(https://www.ascentagepharma.com). Wegreatlyvalueopinionsfromstakeholdersandwelcomeyourfeedbackviathefollowingcontactchannels.YouropinionwillfacilitateusinfurtherimprovingtheReportandenhancetheGroup’soverallESGperformance. Email:ir@ascentage.com Address:68XinqingRoad,SuzhouIndustrialPark,Suzhou,JiangsuPhonenumber:86-21-61951088 AscentagePharmaGroupInternationalEnvironmental,SocialandGovernanceReport2024 3 Environmental,SocialandGovernanceReport2024 HighlightsandPerformance InnovationandResearchandDevelopment(R&D) AnnualR&DinvestmentamountedtoRMB947.2millionWehaveobtainedatotalof16OrphanDrugDesignations(ODDs)fromtheFDAand1ODDfromtheEUfor4oftheCompany’sinvestigationaldrugcandidates;wehavealsoobtained2FastTrackDesignationsand2RarePediatricDisease(RPD)designationsbytheFDADuringtheReportingPeriod,olverembatinibwassuccessfullyincludedintheNationalReimbursementDrugList(NRDL)forBasicMedicalInsurance,Work-RelatedInjuryInsurance,andMaternityInsurance(2024).AllapprovedindicationsofolverembatinibarecoveredbytheNRDL QualityandSafety DuringtheReportingPeriod,AscentagePharmasuccessfullyobtainedISO9001qualitymanagementsystemcertification,covering100%oftheCompany’sproductionfacilitiesZeroproductrecallsforsafetyandhealthreasons EnvironmentandHealth DuringtheReportingPeriod,AscentagePharmasuccessfullyobtainedISO14001environmentalmanagementsystemcertification,covering100%oftheCompany’sproductionfacilitiesAdditionally,AscentageSuzhousecuredtheapprovaltobea2A-levelGreenFactoryinSuzhouIndustrialParkfor2024alongwithobtainingthesecondbatchof3A-levelGreenFactoryinSuzhouZeroincidentsofenvironmentalpollutionandenvironmentaladministrativepenaltiesZerowork-relatedfatalityandinjury EmployeeandCommunity Employeetrainingcoveragereached100%,withanaverageof8.75traininghoursperemployeeEmployeecoveragerateoftheEmployeeStockOwnershipPlanreached100%